BioStock: DexTech’s stock under pressure despite broadened pipeline

The stock market turbulence of recent months has also left its mark on the biotechnology sector, and one of many companies affected is DexTech, whose shares are down 40 per cent since the turn of the year. However, the stock has lost value ever since the phase IIb results in 2018 and the 2-year follow-up in 2020, while the company has continued to pursue partnerships and broaden its pipeline. In this article, BioStock takes a closer look at how the market values the potential that the company believes lies in the research. 

Read the full article at biostock.se:

https://www.biostock.se/en/2022/03/dextechs-stock-under-pressure-despite-broadened-pipeline/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se